TLDR: Korean healthcare AI companies VUNO and Lunit are aggressively pursuing profitability amidst a highly competitive global market. VUNO is projected to achieve profitability in Q2 2025 with strong revenue and operating profit growth, driven by its diverse AI medical devices. Lunit, while setting a new revenue record in Q1 2025, anticipates reaching operating profit by Q4 2026, fueled by strategic partnerships and global expansion despite current losses.
In a rapidly evolving global healthcare technology landscape, South Korean artificial intelligence (AI) firms VUNO and Lunit are making significant strides towards achieving profitability, navigating an increasingly competitive market. Both companies, pioneers in medical AI, are shifting focus from pure technological potential to tangible commercial performance as a key measure for attracting investment and assessing corporate value.
VUNO, established in 2014, is poised to become the first domestic medical AI company to achieve profitability. According to FnGuide on July 22, 2025, VUNO is projected to record an operating profit of 400 million won on revenues of 9.4 billion won in the second quarter of 2025. This represents a substantial year-over-year improvement, with revenue increasing by 46.8% and operating profit by 88.5%. The company, which received Korea’s first AI-based medical device approval in 2018, has demonstrated consistent quarterly performance growth since 2023. VUNO’s product portfolio includes AI solutions for reading chest X-ray images, monitoring cardiac arrest risk, brain quantification, fundus image diagnostic assistance (VUNOmed FundusAI), and bone age diagnosis. Its cardiac arrest risk monitoring product is currently deployed in approximately 120 medical institutions across Korea, covering 62,000 hospital beds, and the company is actively seeking U.S. approval to further expand its global footprint.
Lunit, another prominent first-generation Korean AI firm, has set its sights on achieving operating profit by the fourth quarter of 2026. The company reported a new quarterly revenue record in the first quarter of 2025, reaching 19.23 billion won, a remarkable 273.6% increase compared to the same period last year. Despite this revenue surge, Lunit recorded an operating loss of 20.6 billion won in Q1 2025, a 61% increase in losses attributed to significant investments and operational funds allocated for business expansion. Lunit is strategically partnering with global technology giants like Microsoft (MS) to distribute its AI solutions via MS’s cloud platform, Azure, aiming for a substantial increase in new product supply.
Also Read:
- LG AI Research Unveils Advanced EXAONE Ecosystem at Annual AI Talk Concert 2025
- Indian IT Sector Grapples with Margin Squeeze Amidst Macroeconomic Headwinds and AI Integration
The broader medical AI industry is witnessing intense competition, with commercial performance becoming paramount. Companies are leveraging deep learning, a machine learning method enabling AI to independently learn from vast information and identify patterns, to develop advanced diagnostic and predictive medical devices. This trend extends beyond Korea, with U.S. publicly traded company Tempus AI also targeting profitability this year. Tempus AI’s first-quarter 2025 revenue rose 75% year-over-year to $255.57 million, and its operating loss for the quarter was approximately $68 million, indicating a reduction in its loss margin.
